Isofol´s oncology seminar

Watch the seminar from January 30, 2020 >>

Arfolitixorin - a drug candidate
for treatment of colorectal cancer

See how arfolitixorin
works in cancer cells

See the animation >>

The global Phase III AGENT study

The AGENT study with arfolitixorin

is ongoing at more than 80 hospitals

in The US, Canada, Europe, Australia and Japan

Previous

Next

Startpage 2

Press releases & Latest news

Information in relation to COVID-19

Information in relation to COVID-19

April 2, 2020 by

GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has since the…

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

March 30, 2020 by

GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

March 30, 2020 by

GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

Upcoming Events

May 05, 2020 - May 05, 2020
Extra Ordinary General Meeting
May 14, 2020 - May 14, 2020
Intermin Report Q1 2020
May 14, 2020 - May 14, 2020
Annual General Meeting 2020
August 21, 2020 - August 21, 2020
Intermin Report Q2 2020